Profile data is unavailable for this security.
About the company
Omega Therapeutics, Inc. is a clinical-stage biotechnology company, which is engaged in the development of a programmable epigenomic mRNA medicine to treat or cure a broad range of diseases. The Company’s OMEGA platform has enabled it to identify and validate various DNA-sequence-based epigenomic, zip codes, associated with individual regulatory elements within Insulated Genomic Domains (IGDs). The Company designs and engineers its mRNA therapeutics, called epigenomic controllers, or ECs, to target EpiZips for precision epigenomic control. Its pipeline consists of programs that span oncology, regenerative medicine, and multigenic diseases including immunologic and cardiometabolic conditions. The Company’s precision epigenomic control delivered by the OMEGA platform has therapeutic applicability and transformational potential, spanning across oncology, multigenic diseases including immunologic and cardiometabolic conditions, and regenerative medicine.
- Revenue in USD (TTM)4.94m
- Net income in USD-92.28m
- Incorporated2016
- Employees93.00
- LocationOmega Therapeutics Inc140 First Street, Suite 501CAMBRIDGE 02141United StatesUSA
- Phone+1 (617) 949-4360
- Fax+1 (302) 655-5049
- Websitehttps://omegatherapeutics.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Allakos Inc | 0.00 | -214.44m | 127.50m | 131.00 | -- | 1.22 | -- | -- | -2.45 | -2.45 | 0.00 | 1.18 | 0.00 | -- | -- | 0.00 | -81.27 | -42.71 | -92.78 | -45.11 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 41.96 | -- | -38.89 | -- |
| FitLife Brands Inc | 58.51m | 7.30m | 127.60m | 37.00 | 18.76 | 4.34 | 17.22 | 2.18 | 1.48 | 1.48 | 11.87 | 6.39 | 1.20 | 3.87 | 27.13 | 1,581,351.00 | 15.03 | 26.40 | 19.37 | 33.92 | 41.55 | 42.09 | 12.48 | 17.65 | 0.5177 | 12.32 | 0.3582 | -- | 82.97 | 25.28 | 19.58 | 67.31 | -- | -- |
| Coya Therapeutics Inc | 6.13m | -10.30m | 127.62m | 8.00 | -- | 3.94 | -- | 20.82 | -0.8899 | -0.8899 | 0.5401 | 2.22 | 0.2236 | -- | -- | 766,131.30 | -37.59 | -- | -41.86 | -- | -- | -- | -168.11 | -- | -- | -- | 0.00 | -- | -- | -- | 34.77 | -- | -- | -- |
| PDS Biotechnology Corp | 0.00 | -43.89m | 128.01m | 25.00 | -- | 3.44 | -- | -- | -1.37 | -1.37 | 0.00 | 1.01 | 0.00 | -- | -- | 0.00 | -63.85 | -51.63 | -74.22 | -59.00 | -- | -- | -- | -- | -- | -27.82 | 0.3933 | -- | -- | -- | -5.11 | -- | -- | -- |
| Regulus Therapeutics Inc | 0.00 | -31.37m | 130.93m | 28.00 | -- | 1.22 | -- | -- | -1.46 | -1.46 | 0.00 | 1.64 | 0.00 | -- | -- | 0.00 | -41.50 | -53.74 | -45.91 | -76.96 | -- | -- | -- | -715.58 | -- | -- | 0.005 | -- | -- | -- | -6.05 | -- | 94.54 | -- |
| Adicet Bio Inc | 0.00 | -139.79m | 131.48m | 143.00 | -- | 0.5080 | -- | -- | -2.95 | -2.95 | 0.00 | 3.15 | 0.00 | -- | -- | 0.00 | -46.75 | -37.03 | -49.70 | -40.28 | -- | -- | -- | -748.46 | -- | -- | 0.00 | -- | -100.00 | -- | -104.41 | -- | 65.27 | -- |
| Biostem Technologies Inc | 16.69m | -7.86m | 131.99m | 67.00 | -- | -- | -- | 7.91 | -0.5699 | -0.5699 | 1.21 | -0.0607 | -- | -- | -- | -- | -- | -- | -- | -- | 92.44 | -- | -47.12 | -- | 0.7825 | -10.22 | 1.26 | -- | -- | -- | -- | -- | -- | -- |
| Vigil Neuroscience Inc | 0.00 | -82.78m | 132.30m | 65.00 | -- | 1.27 | -- | -- | -2.12 | -2.12 | 0.00 | 2.76 | 0.00 | -- | -- | 0.00 | -52.16 | -- | -54.92 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -20.98 | -- | -- | -- |
| Omega Therapeutics Inc | 4.94m | -92.28m | 132.92m | 93.00 | -- | 3.21 | -- | 26.91 | -1.67 | -1.67 | 0.0896 | 0.7498 | 0.029 | -- | 6.08 | 53,107.53 | -54.28 | -- | -62.10 | -- | -- | -- | -1,868.35 | -- | -- | -- | 0.302 | -- | 49.25 | -- | 5.13 | -- | -- | -- |
| Sangamo Therapeutics Inc | 18.76m | -328.05m | 134.79m | 405.00 | -- | 2.33 | -- | 7.19 | -1.86 | -1.86 | 0.1057 | 0.2784 | 0.0659 | -- | 4.86 | 46,311.11 | -115.20 | -26.09 | -139.17 | -31.04 | -- | -- | -1,749.06 | -136.53 | -- | -- | 0.00 | -- | 58.34 | 15.85 | -34.09 | -- | -13.25 | -- |
| Tevogen Bio Holdings Inc | 0.00 | -67.33k | 134.98m | 17.00 | -- | -- | -- | -- | -0.0004 | -0.0004 | 0.00 | -0.0045 | -- | -- | -- | 0.00 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -8.19 | 1.74 | -- | -- | -- | 99.69 | -- | -- | -- |
| Karyopharm Therapeutics Inc | 140.46m | -146.34m | 135.37m | 325.00 | -- | -- | -- | 0.9637 | -1.28 | -1.28 | 1.22 | -1.45 | 0.5298 | 1.67 | 4.24 | 432,187.70 | -55.19 | -53.02 | -72.56 | -65.85 | 96.08 | 97.18 | -104.18 | -125.15 | 2.99 | -9.66 | 2.25 | -- | -7.03 | 36.93 | 13.43 | -- | -- | -- |
| Bioatla Inc | 0.00 | -119.24m | 136.14m | 65.00 | -- | 2.74 | -- | -- | -2.49 | -2.49 | 0.00 | 1.03 | 0.00 | -- | -- | 0.00 | -81.18 | -48.72 | -96.07 | -57.35 | -- | -- | -- | -6,651.71 | -- | -- | 0.00 | -- | -- | -- | -15.95 | -- | -37.01 | -- |
| aTyr Pharma Inc | 588.00k | -53.93m | 138.02m | 56.00 | -- | 1.62 | -- | 234.73 | -0.9029 | -0.9029 | 0.0099 | 1.24 | 0.0047 | -- | 0.2868 | 10,500.00 | -43.13 | -45.45 | -48.85 | -52.74 | -- | -- | -9,172.11 | -784.19 | -- | -- | 0.021 | -- | -96.60 | -- | -11.14 | -- | 47.98 | -- |
Data as of May 17 2024. Currency figures normalised to Omega Therapeutics Inc's reporting currency: US Dollar USD
26.91%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| Fidelity Management & Research Co. LLCas of 31 Mar 2024 | 6.29m | 11.41% |
| State of Wisconsin Investment Boardas of 31 Mar 2024 | 1.86m | 3.37% |
| Invus Public Equities Advisors LLCas of 31 Mar 2024 | 1.32m | 2.40% |
| BlackRock Fund Advisorsas of 31 Mar 2024 | 1.31m | 2.37% |
| The Vanguard Group, Inc.as of 31 Mar 2024 | 1.23m | 2.24% |
| Platinum Investment Management Ltd.as of 31 Mar 2024 | 886.78k | 1.61% |
| Geode Capital Management LLCas of 31 Mar 2024 | 500.50k | 0.91% |
| Point72 Asset Management LPas of 31 Mar 2024 | 482.88k | 0.88% |
| SSgA Funds Management, Inc.as of 31 Mar 2024 | 481.58k | 0.87% |
| Citigroup Global Markets, Inc. (Investment Management)as of 31 Mar 2024 | 479.02k | 0.87% |
More ▼
Data from 31 Mar 2024 - 31 Mar 2024Source: FactSet Research Systems Inc.
